Storage, cold chain, and beyond-use dates

Peptide products are assigned one of several labeled storage conditions based on stability data under ICH Q1A guidelines:

The cold chain encompasses all steps from manufacturing through administration during which a product requiring controlled temperature (typically 2--8°C, or −20°C for frozen products) must maintain those conditions. Breaches can occur during:

• Warehousing and distribution

• Pharmacy receipt and storage

• Patient transport and home storage

• Administration (handling time outside refrigeration)

Validated cold-chain documentation uses continuous temperature monitoring (e.g., data loggers with alarms, RFID tags, or phase-change indicators). WHO facilities typically require temperature mapping of storage areas.

Freeze-thaw effects

Freezing is damaging for most liquid peptide products:

• Ice crystal formation can denature peptides and proteins

• Cryoconcentration of solutes can cause precipitation or pH shifts

• Thawing may not restore native conformation

Products labeled "Do not freeze" must be protected from unintended freezing during transport, which can occur in cold climates or refrigerator cold spots (e.g., near the cooling element).

For lyophilized products, the cake itself must not be exposed to temperatures above its glass-transition temperature (Tg), where increased molecular mobility can lead to collapse, loss of porosity, and accelerated degradation.

Stability testing under ICH Q5C for biotechnological/biological products requires, at a minimum, assessment of:

• Potency (bioassay or HPLC for small peptides)

• Purity (aggregates, degradation products by HPLC)

• Physical appearance (clarity, color, particulates)

• pH (for liquid products or after reconstitution)

• Moisture content (for lyophilized)

• Subvisible particles (USP <787>/<788>)

• Container-closure integrity

Forced degradation studies (e.g., elevated temperature, light, humidity, oxidation) identify degradation pathways and establish the stability-indicating nature of the analytical methods.

Regulatory BUD vs. labeled expiration vs. in-use period

• Expiration date (shelf life): The date assigned by the manufacturer and regulatory authority based on full stability data. It applies to an unopened product stored under labeled conditions.

• In-use period: For an approved manufactured product, the period after first opening or reconstitution during which the product may be used. This is determined by the manufacturer from in-use stability studies and stated on the approved label.

• Beyond-use date (BUD): For a compounded preparation, the date after which the preparation should not be used. The BUD is assigned by the compounding pharmacist based on the applicable standards (e.g., USP <797>), the preparation category, sterility controls, storage conditions, and available stability and sterility evidence. It is a professional compounding determination, not a manufacturer-set date.

BUD for reconstituted products

There is no defensible generic beyond-use period for a reconstituted peptide. Single-dose and multi-dose presentations, preservatives, container closure, validated microbial controls, chemical stability, and label wording differ. The manufacturer's labeled in-use period governs approved products; a compounding pharmacist assigns a compounded preparation's BUD under the applicable standards and supporting data. The familiar “28-day” convention is not a universal peptide rule.

USP <797> BUD for compounded sterile preparations

The current USP <797> framework uses preparation category, processing method, sterility controls, environment, storage condition, and—where applicable— stability and sterility evidence. Older “low/medium/high risk” default tables are not a current shortcut. Different jurisdictions use different standards, and a BUD assignment is professional compounding work rather than a home calculation.

Many peptides are light-sensitive, particularly those containing tryptophan, tyrosine, or phenylalanine residues (which absorb UV light), or methionine and cysteine (which undergo photooxidation).

Labeled requirements include "Store in original carton" (e.g., many GLP-1 products) or "Protect from light." The outer carton provides sufficient light protection for the labeled shelf life; after removal from the carton, the product should be protected from direct sunlight and strong artificial light.

For lyophilized products that are reconstituted at the time of use, the cake must remain sealed until use. Residual moisture content is controlled during manufacturing (typically <1--2%). If the vial seal is compromised or the product is stored in a high-humidity environment, moisture ingress can plasticize the cake, lower Tg, and accelerate degradation.

A product that has been dispensed as a dry powder (lyophilized) and stored under proper conditions may have a different container-closure and stability profile than the equivalent liquid product. Lyophilization generally provides longer shelf life (often 2--3 years vs. 1--2 years for a liquid formulation of the same peptide).

1. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products (Q1A(R2)). 2003. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf

2. ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (Q5C). 1995. https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf

3. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.

4. WHO. WHO Technical Report Series, No. 953, Annex 5: Good Distribution Practices for Pharmaceutical Products. 2010.

5. FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008.

6. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969--975. https://doi.org/10.1023/a:1012180707283

7. USP General Chapter <659> Packaging and Storage Requirements. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.